JASPER THERAPEUTICS INC

JSPRNASDAQ

🏆 #3467 by market capEarnings Aug 11 · PreUS Equity

$0.89▲ $0.10 (+11.72%)

Live

1h—

24h▲ 11.7%

7d—

14d—

30d—

1y—

🏦Market Cap

$30M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

No chart data available for JSPR.

Trading Snapshot

Day Range: $0.89 – $0.91
52-Week Range: $0.32 – $3.14
Volume: $4.44B
Avg Volume: $3.24B
Shares Outstanding: 33.3M
Next Earnings: Sep 8, 2026

Fundamentals Snapshot

Annual Revenue: $3M
Last Q Revenue: $859,325
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-3.23
Dividend Yield: —

Why Investors Own JSPR

✓High-growth profile — revenue up -6.2% YoY with expanding US Equity exposure.
✓Healthy economics — 30% gross margin and 22% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$3M▼ −5.0% YoY

Gross Margin (TTM)

29.5%▼ −0.2% YoY

Operating Income (TTM)

$814,723▼ −5.0% YoY

Free Cash Flow (TTM)

$690,119▼ −5.0% YoY

About JASPER THERAPEUTICS INC

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.

🦦